<DOC>
	<DOCNO>NCT02033096</DOCNO>
	<brief_summary>Follow-up , Having Received Stannsoporfin Placebo Clinical Trial 64,185-202</brief_summary>
	<brief_title>Follow-up , Blinded-Outcomes Trial Subjects Having Received IMP Clinical Trial 64,185-202</brief_title>
	<detailed_description />
	<mesh_term>Jaundice</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Hyperbilirubinemia , Neonatal</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Subjects receive IMP clinical trial 64,185202 â€¢ Written inform consent provide parents/guardians</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stannsoporfin</keyword>
	<keyword>hyperbilirubinemia</keyword>
	<keyword>heme oxygenase</keyword>
</DOC>